Skip to content

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis

Patients diagnosed with mild to moderate psoriasis vulgaris, chronic plaque type, with PASI score not more than 10 1

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. Purpose This study will evaluate the clinical efficacy, patients quality of life, satisfaction, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in subjects with moderate plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the Extension Phase of the trial. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production. A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. Parapsoriasis, Plaque Psoriasis, CC-10004, Apremilast, Moderate Plaque Psoriasis, and Safety.

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis 2A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. Clinical Trials, 2015. View rest of article at clinicaltrials.gov. This phase 4 trial studying apremilast in subjects with moderate psoriasis involving 5-10 body surface area. At Celgene, we seek to deliver truly innovative and life-changing treatments for our patients.

The registry will be a collection of information about patients with Psoriasis, a chronic skin disease with an unknown cause. Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. PI): A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa Study description not available IRB No. Bruce Strober, PI): A Phase 4, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate Plaque Psoriasis In this study for patients with moderate psoriasis, patients who are randomized to the apremilast treatment group will receive apremilast 30 mg tablets orally twice daily for 52 weeks. The Clinical Trials Unit (CTU) maintains a professional infrastructure for testing new agents and protocols for patients with skin diseases. A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3. EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS. 015Apr. A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. Status: Active, not recruiting. Study Phase: Phase 4.

A Phase 4 Study Of Efficacy And Safety Of Apremilast In Subjects With Moderate Plaque Psoriasis

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis 3The efficacy and safety of apremilast in the treatment of psoriasis have been demonstrated in phase II and III clinical trials. Apremilast demonstrated efficacy in reducing the severity of moderate to severe plaque psoriasis. Hugin, President and CEO, gave guidance for the Apremilast in Plaque Psoriasis ESTEEM program. 6 phase III trials are studying the efficacy and safety of Apremilast in psoriasis and psoriatic arthritis and are accruing ahead of schedule. (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis Estimated Enrollment: 825 Study Start Date: August 2010 Estimated Study Completion Date: June 2016 Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure) Source: clinical trials. We evaluated the efficacy and safety of apremilast in palm. Apremilast was approved for treatment of plaque psoriasis in patients:. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. Clinical Trials Trial – CNS Tumor A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II, multicenter, open-label study evaluated the efficacy, tolerability, and pharmacodynamics of apremilast in patients with recalcitrant plaque psoriasis. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.

Uconn Clinical Trials